China is one of the largest medical device markets in the world, and no device may be imported for sale until it is registered or filed with the NMPA. This guide walks through the complete NMPA registration pathway for foreign manufacturers — who approves what, the dossier, testing, clinical evaluation, statutory review timelines and what happens after approval. It follows China’s current core regulations: the Regulations on the Supervision and Administration of Medical Devices (State Council Decree No. 739, effective June 1, 2021) and the Provisions for Medical Device Registration and Filing (SAMR Order No. 47, effective October 1, 2021).
1. Who approves what: the NMPA structure in brief
The National Medical Products Administration (NMPA) is the national regulator; its technical review body is the Center for Medical Device Evaluation (CMDE). Under Order No. 47 (Articles 4 and 8):
- Imported Class I devices — record-filing (备案) submitted to the NMPA;
- Imported Class II and Class III devices — registration reviewed and approved by the NMPA (CMDE conducts the technical review). Domestic Class II products are approved provincially, but that route does not apply to imported devices.
China applies risk-based classification: Class I (low risk) is filed, Class II (moderate risk) and Class III (high risk) are registered — Decree No. 739, Article 13. There is no import exemption from this system: foreign and domestic products follow the same risk classes. In practice, NMPA registration for foreign manufacturers always starts here: the class decides the authority, the procedure and the evidence package.
2. Step 1 — Confirm your classification
Everything downstream depends on the class. Classification follows the Medical Device Classification Catalogue (22 sub-catalogues, issued by Announcement No. 104 of 2017 and adjusted dynamically) and the Classification Rules. Check the catalogue entry that matches your intended use, structure and contact duration. If your product is new or its class is unclear, a formal classification determination can be requested from the NMPA — decided within 20 working days of acceptance (Decree No. 739, Article 23). Classification should be confirmed before any dossier work: a wrong class is among the most expensive rework errors in practice.
3. Step 2 — Appoint a China legal agent
Overseas applicants and filers must designate an enterprise legal person domiciled in China as their agent, who handles registration and filing matters and assists in fulfilling the registrant’s legal obligations (Order No. 47, Article 14; Decree No. 739, Articles 15, 16 and 20). The agent is a regulatory role — distinct from a distributor — and its name, address and contact details must appear in the dossier and on Chinese labels and instructions for use. See our detailed article on the China legal agent: duties, requirements and how to change one, or engage INTERBRI directly as your China medical device agent.
4. Step 3 — Prepare the registration dossier
The submission dossier follows the seven statutory sections (Decree No. 739, Article 14; Order No. 47, Article 52):
| Dossier section | What it covers |
|---|---|
| 1. Risk analysis | Risk management documentation for the product |
| 2. Product technical requirements (PTR) | Objectively verifiable performance and safety indicators with test methods — the benchmark production is later audited against |
| 3. Test report | Type testing against the PTR — self-testing or an accredited laboratory (see Step 4) |
| 4. Clinical evaluation | Exemption, same-variety evaluation or clinical trial route (see Step 5) |
| 5. IFU and label drafts | Chinese instructions for use and labeling samples |
| 6. QMS documentation | Quality management system documents related to design and production |
| 7. Supporting evidence | Proof of marketing authorization in the home country (Order No. 47, Article 18), power of attorney, agent agreement and other materials |
Dossiers must be in Chinese; foreign-language materials are submitted with the original text attached (Order No. 47, Article 17). Notarization and legalization requirements apply to several overseas-issued documents, so start document preparation early.
5. Step 4 — Testing: type testing or self-testing
The test report may be issued either by the applicant itself (self-testing) or by a qualified medical device laboratory (Decree No. 739, Article 14; Order No. 47, Article 32). Samples used for testing must be representative of the registered product and produced under GMP conditions (Order No. 47, Articles 30–31). Self-testing is a genuine option since the 2021 revision, but reviewers will scrutinize the laboratory capability behind the report, and QMS verification will re-check testing capability where self-test reports are submitted.
6. Step 5 — Clinical evaluation
Clinical evaluation is required unless the product qualifies for exemption. Three routes exist: the exemption catalogue (for mature devices with established equivalents), same-variety clinical evaluation (comparison against an equivalent device plus its clinical data), and clinical trials. High-risk Class III trials additionally require NMPA approval before starting. We cover the routes in detail in our article on clinical evaluation in China.
7. Step 6 — Submission, acceptance and fees
Applications are submitted online. The authority checks the dossier on receipt; where documents are incomplete it must issue a single consolidated correction notice within 5 days, and the application is deemed accepted if no such notice is issued in time (Order No. 47, Article 53). Registration fees are charged per the schedules published by the finance and pricing authorities (Order No. 47, Article 120); failing to pay on time is treated as withdrawal.
8. Step 7 — Technical review: the statutory clocks
Once accepted, the application moves to technical review. The working-day limits are set by Order No. 47, Articles 90–99:
| Stage | Class II | Class III |
|---|---|---|
| Transfer to technical review | 3 working days after acceptance | |
| Technical review (initial) | 60 working days | 90 working days |
| Review after supplement | 60 working days | |
| QMS verification (if required) | Notified within 10 days; completed within 30 days in principle | |
| Decision after review opinion | 20 working days | |
| Certificate issuance | Within 10 days of the decision | |
Important mechanics: the reviewer must request all missing information in one notice, and the applicant has one year to respond once (Order No. 47, Article 54) — missing the window terminates the review. Extensions may not exceed one half of the original limit (Article 96), and time spent on supplements, QMS verification and expert consultation does not count toward the clocks (Article 98). This is why real-world durations run longer than the statutory review clocks.
9. Step 8 — Decision, certificate and validity
Approved devices receive a registration certificate valid for 5 years (Decree No. 739, Article 22). Plan renewal early: a renewal application must be filed with the original authority 6 months before expiry, and late applications are refused. Changes after approval follow the change-registration and record-change rules (Order No. 47, Articles 79–81).
10. How long does China registration actually take?
Two lenses answer this honestly. The statutory clocks (above) add up to roughly 83 working days for Class II and 113 working days for Class III in the best case — before extensions. The end-to-end duration additionally includes preparation, testing, clinical evaluation and deficiency cycles, which the law does not clock. Published industry estimates for imported devices generally land at: Class I filing — weeks to a few months; Class II — roughly 12–24 months; Class III — roughly 18–36 months, with high-risk or clinical-trial products at the upper end. These ranges are secondary-source estimates (e.g., Pacific Bridge Medical, Qserve), not commitments: actual timelines depend on the product, evidence readiness and review workload.
11. What does registration cost?
Costs have four components. (1) Official fees — application categories (first registration, change, renewal) follow published government fee schedules; imported Class II/III are reviewed nationally while domestic Class II fees are set provincially. (2) Type testing — laboratory fees depend on standards and test scope. (3) Clinical evaluation — from literature-based evaluation to full trials, the widest cost variable. (4) Agent and consulting fees — the China legal agent and regulatory support. We do not quote unverified figures here: official fee schedules change, and per-product scope drives the rest — ask us for a product-specific estimate.
12. After approval: what keeps the certificate alive
Approval starts, not ends, the compliance work: UDI submission per the rollout batches (Order No. 47, Article 101), Chinese labeling for every imported unit (Decree No. 739, Articles 39 and 57), adverse event monitoring and reporting, recall readiness, and distribution-side licensing for your China channel (Articles 41–42). Overseas holders carry the same post-market duties as domestic registrants, implemented with the China legal agent’s support.
